VI-RADS前瞻性评估及其对高危非肌层浸润性膀胱癌重复电切决策的影响
该前瞻性研究纳入231例膀胱癌疑似患者,在经尿道膀胱肿瘤电切术(TURBT)前行多参数磁共振成像(mpMRI)并以VI-RADS≥3定义肌层浸润性膀胱癌(MIBC)。结果显示VI-RADS区分非肌层浸润性膀胱癌(NMIBC)与MIBC的AUC为0.94;在114例高危NMIBC患者中,预测重复TURBT时MIBC的AUC为0.93。VI-RADS有望优化高危NMIBC患者重复TURBT的选择。
要点
- VI-RADS≥3区分NMIBC与MIBC的敏感度91.9%、特异度91.1%、AUC 0.94。
- 高危NMIBC中预测重复TURBT时MIBC的AUC为0.93,阴性预测值96.6%。
- VI-RADS可能帮助筛选可避免重复TURBT的高危NMIBC患者。
核心结论
- VI-RADS能准确区分NMIBC与MIBC。
- 在高危NMIBC患者中,VI-RADS未来可能改善重复TURBT候选者的筛选。
研究设计与样本
- 前瞻性研究,共纳入231例膀胱癌疑似患者,TURBT前接受膀胱多参数MRI。
- 假定VI-RADS cutoff≥3定义MIBC,将TURBT报告与术前VI-RADS评分比较。
- 高危NMIBC患者(n=114)的重复TURBT报告与术前VI-RADS评分比较。
主要发现
- 初诊TURBT区分NMIBC与MIBC:敏感度91.9%(95%CI 82.2-97.3)、特异度91.1%(95%CI 85.8-94.9)、PPV 77.5%(95%CI 65.8-86.7)、NPV 97.1%(95%CI 93.3-99.1)、AUC 0.94(95%CI 0.91-0.97)。
- 高危NMIBC患者预测重复TURBT时MIBC:敏感度85%(95%CI 62.1-96.8)、特异度93.6%(95%CI 86.6-97.6)、PPV 74.5%(95%CI 52.4-90.1)、NPV 96.6%(95%CI 90.5-99.3)、AUC 0.93(95%CI 0.87-0.97)。
关键数值与推荐
- VI-RADS cutoff≥3定义为MIBC。
- 采用敏感度、特异度、PPV、NPV及ROC曲线评估mpMRI性能。
- 采用Ƙ统计评估阅片者间及阅片者内变异。
临床怎么用
- TURBT前mpMRI的VI-RADS评分可用于术前膀胱癌分期,辅助区分NMIBC与MIBC。
- 对高危NMIBC患者,VI-RADS可能作为术前预测工具,筛选可避免重复TURBT者并识别重复TURBT时MIBC高风险者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vesical Imaging Reporting and Data System (VI-RADS) score is adopted to provide preoperative bladder cancer (BCa) staging. Repeated transurethral resection of bladder tumor (Re-TURBT) is recommended in most of high-risk non-muscle-invasive bladder cancers (HR-NMIBCs) due to possibility of persistent/understaged disease after initial TURBT. No diagnostic tools able to improve patient's stratification for such recommendation exist. OBJECTIVE: To (1) prospectively validate VI-RADS for discriminating between NMIBC and muscle-invasive bladder cancer (MIBC) at TURBT, and (2) evaluate the accuracy of VI-RADS for identifying HR-NMIBC patients who could avoid Re-TURBT and detecting those at higher risk for understaging after TURBT. DESIGN, SETTING, AND PARTICIPANTS: Patients with BCa suspicion were offered multiparametric magnetic resonance imaging (mpMRI) before TURBT. According to VI-RADS, a cutoff of ≥3 to define MIBC was assumed. TURBT reports were compared with preoperative VI-RADS scores to assess accuracy of mpMRI for discriminating between NMIBC and MIBC. HR-NMIBC Re-TURBT reports were compared with preoperatively recorded VI-RADS scores to assess mpMRI accuracy in predicting Re-TURBT outcomes. INTERVENTION: Multiparametric MRI of the bladder before TURBT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values were calculated for mpMRI performance in patients undergoing TURBT and for HR-NMIBC patients candidate for Re-TURBT. Performance of mpMRI was assessed by receiver operating characteristic curve analysis. Ƙ statistics was used to estimate inter- and intrareader variability. RESULTS AND LIMITATIONS: A total of 231 patients were enrolled. Multiparametric MRI showed sensitivity, specificity, PPV, and NPV for discriminating NMIBC from MIBC at initial TURBT of 91.9% (95% confidence interval [CI]: 82.2-97.3), 91.1% (95% CI: 85.8-94.9), 77.5% (95% CI: 65.8-86.7), and 97.1% (95% CI: 93.3-99.1), respectively. The area under the curve (AUC) was 0.94 (95% CI: 0.91-0.97). Among HR-NMIBC patients (n=114), mpMRI before TURBT showed sensitivity, specificity, PPV, and NPV of 85% (95% CI: 62.1-96.8), 93.6% (95% CI: 86.6-97.6), 74.5% (95% CI: 52.4-90.1), and 96.6% (95% CI: 90.5-99.3) respectively, to identify patients with MIBC at Re-TURBT. The AUC was 0.93 (95% CI: 0.87-0.97). CONCLUSIONS: VI-RADS is accurate for discriminating between NMIBC and MIBC. Within HR-NMIBC cases, VI-RADS could, in future, improve the selection of patients who are candidate for Re-TURBT. PATIENT SUMMARY: We investigated the accuracy of Vesical Imaging Reporting and Data System (VI-RADS) score to asses bladder cancer staging before transurethral resection of bladder tumors, and we explored the performance of VI-RADS score as a future preoperative predictive tool for the selection of high-risk non-muscle-invasive bladder cancer patients who are candidate for undergoing early repeated transurethral resection of the primary tumor site.
引用
- Del Giudice F, Barchetti G, De Berardinis E, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol. 2019. PMID: 31699526. doi:10.1016/j.eururo.2019.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。